Allergologia et immunopathologia最新文献

{"title":"A Delphi consensus on diagnosis, management, and treatment with allergen immunotherapy of polysensitized children in Spain: CAPP study, Part 1.","authors":"María Mesa-Del-Castillo, Francisco J Canals Candela, Ana Martínez-Cañavate, Cristina Rivas-Juesas, Helena Larramona Cabrera, Miguel Tortajada-Girbés, José Manuel Lucas Moreno, Maria Del Mar Folqué, Ana Morales-Tirado, Ana I Tabar","doi":"10.15586/aei.v53i2.1220","DOIUrl":"10.15586/aei.v53i2.1220","url":null,"abstract":"<p><strong>Background: </strong>The study aimed to evaluate the level of agreement between specialists in pediatric allergology regarding the diagnosis and indications for pollen allergen immunotherapy (AIT) of polysensitized children in Spain.</p><p><strong>Materials and methods: </strong>A Delphi study was performed using an online survey designed by a committee of pediatric AIT experts: 46 and 44 panelists participated in rounds 1 and 2, respectively. In round 1, 204 statements on 8 dimensions were evaluated (Diagnosis; Therapeutic management; Pollens - Part I; Mites; Moulds; Animals; Hymenoptera venom; and Mixtures - Part II). A total of 148 statements were finally accepted after round 2. Panel members rated their level of agreement with assessments on a 9-point Likert scale based on acceptance by ≥ 66.7% of them.</p><p><strong>Results: </strong>According to the results, the polysensitization determination in allergic patients is confirmed by clinical history, skin prick test, total and specific IgE, and molecular diagnostics. Clinical assessments are recommended for the AIT effectiveness evaluation. Follow-ups should be performed 6 months after AIT initiation. According to experts, pollens are the most representative allergens in allergic rhinitis but AIT is more effective in bronchial asthma treatment. The IgE levels are positively related to the intensity of the symptomatology and the efficacy of <i>Grass</i> AIT. In pollen mixtures, a maximum mixture of three AIT allergens is established between <i>Grass, Olive</i>, and <i>Cupressaceae</i>. Mixing pollen from <i>Platanus acerifolia</i> and <i>Parietaria</i> is not recommended.</p><p><strong>Conclusions: </strong>This study provides, where evidence is lacking, current expert-based opinions on clinical decision-making for managing pollen AIT in polysensitized children.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"124-140"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between e-cigarette smoking and different lifestyle patterns among young adults in Saudi Arabia.","authors":"Shatha A Alduraywish, Abdulrahman A Alghamdi, Mohammed A Almutairi, Faisal M Alghthami, Mohand M Alsultan, Laith A Alreshaid, Fahad M Aldakheel, Shabana Tharkar","doi":"10.15586/aei.v53i2.1222","DOIUrl":"10.15586/aei.v53i2.1222","url":null,"abstract":"<p><strong>Background: </strong>E-cigarette use has been linked with multiple morbidities and changes in health behavior. This study investigates e-cigarette use with sleep patterns, stress levels, and physical activity behavior and compare it with nonsmokers.</p><p><strong>Methods: </strong>A standardized electronic questionnaire for sleep, stress, and physical activity assessment was used on 372 students enrolled in a large university. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 23.0.</p><p><strong>Results: </strong>The mean age of the study population was around 20 years, with e-cigarette use higher in males. The mean age of smoking initiation was 17 years. The intention to play sports and physical activity differed between smokers and nonsmokers. E-cigarette users practiced sports to remain fit while nonsmokers intended to play sports for enjoyment; however, no significant difference in the level of fitness was found. Sleep behavior and stress levels were similar across the two groups.</p><p><strong>Conclusion: </strong>No difference in lifestyle patterns between e-cigarette users and nonsmokers may be due to lesser smoking duration since initiation. Longitudinal studies with diverse populations and a longer duration of e-cigarette use are recommended to explore the effects of e-cigarette smoking on lifestyle behavior.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"67-73"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life effectiveness of tezepelumab in severe asthma.","authors":"Juan Carlos Miralles-López, Francisco-José Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Mercedes Ramírez-Hernández, Sheila Cabrejos-Perotti, Maria Jesús Avilés-Inglés, Inmaculada Ibarra-Calabuig, Miguel Henrique Reyes-Cotes, Manuel José Pajarón-Fernández, Roberto Bernabéu-Mora, Consuelo Alcalde-Rumayor, María Loreto Alemany-Francés, José Valverde-Molina, Virginia Pérez-Fernández","doi":"10.15586/aei.v53i2.1326","DOIUrl":"10.15586/aei.v53i2.1326","url":null,"abstract":"<p><strong>Background: </strong>Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes.</p><p><strong>Methods: </strong>This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions.</p><p><strong>Results: </strong>We present a series of 57 patients who completed at least 6 months of treatment with tezepelumab. The exacerbations decreased from a baseline mean of 2.63 in the previous year to a <i>mean annual rate</i> of 0.38 after 6 months of tezepelumab (85.6% decrease). The Asthma Control Test score increased by 5.3 points, and the Mini Asthma Quality of Life Questionnaire score increased by 0.94 points. Regarding lung function, we obtained a significant increase of 188 mL in forced expiratory volume in 1 s and 166 mL in forced vital capacity. Finally, type-2 (T2) biomarkers, such as eosinophils and nitric oxide, showed a significant decrease. We compared the results in patients with or without previous biological treatment as well as in patients with or without allergy sensitization, and we did not obtain significant differences in any variable.</p><p><strong>Conclusions: </strong>Tezepelumab is an effective treatment for severe asthma, lessening exacerbations, controlling the disease, and improving quality of life and lung function in patients with and without high T2 biomarkers, regardless of previous biological treatment.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"163-173"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lysine hydroxylase 1 (PLOD1) regulates glucose metabolism and promotes Th17 cell differentiation in psoriasis.","authors":"Zhen Yue, Wanlu Zhang, Gege Zhu, Huiya Sun, Congjun Jiang","doi":"10.15586/aei.v53i2.1269","DOIUrl":"10.15586/aei.v53i2.1269","url":null,"abstract":"<p><p>Psoriasis is a common and chronic inflammatory skin disease. To treat psoriasis, more effective molecular targets still need to be developed and the mechanisms elucidated. PLOD1, as one of the genes related to glycolysis, can promote the glycolysis of cells. However, it is not clear whether upregulation of PLOD1 plays a causal role or is directly involved in psoriasis. Herein, we have examined the PLOD1 expression in patients with psoriasis and analyzed its effect on the progression of psoriasis. We found that PLOD1 is highly expressed in psoriasis. Also, the role of PLOD1 in promoting Th17 cell differentiation was further revealed, and PLOD1 promotes T cell glycolysis. Mechanically, PLOD1 activates the PI3K/AKT/mTOR pathway and thereby affects the progression of psoriasis. In conclusion, PLOD1 regulates glucose metabolism and promotes Th17 cell differentiation, which affects the progression of psoriasis.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"74-81"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Xuanbai Chengqi decoction combined with western medicine in treating AECOPD with phlegm-heat obstructing lung syndrome: a clinical study.","authors":"Quan He, Guangfei Wei, Xuzhi Lu, Weiqi Feng, Meiyue Yu, Xiaomei Ma","doi":"10.15586/aei.v53i2.1180","DOIUrl":"10.15586/aei.v53i2.1180","url":null,"abstract":"<p><strong>Objective: </strong>To explore the efficacy of Xuanbai Chengqi Decoction combined with conventional Western medicine in the treatment of AECOPD patients with phlegm-heat obstructing the lung syndrome.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 166 patients with this syndrome admitted to our hospital between December 2023 and March 2024. Patients were divided into a study group (Xuanbai Chengqi Decoction + conventional Western medicine treatment, 83 cases) and a control group (conventional Western medicine treatment, 83 cases). The clinical efficacy, Traditional Chinese Medicine (TCM) syndrome scores, blood routine indicators, inflammatory factors, and other clinical outcomes were compared between the two groups.</p><p><strong>Results: </strong>Before treatment, there were no significant differences in the above-mentioned indicators between the two groups (P > 0.05). After treatment, the study group showed a significantly higher overall effective treatment rate, lymphocyte percentage, SOD, and NO levels, and a significantly lower TCM syndrome score, neutrophil percentage, white blood cell count, TNF-α, IL-6, CRP, and MOD levels, with statistical significance (P < 0.05).</p><p><strong>Conclusion: </strong>Xuanbai Chengqi Decoction combined with Western medicine treatment can effectively alleviate the clinical symptoms of AECOPD patients with phlegm-heat obstructing the lungs syndrome, improve blood routine indicators, control inflammation, and enhance the overall therapeutic effect.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"100-107"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The cause of perioperative hypersensitivity in adults and consequences of subsequent anesthesia.","authors":"Zeynep Yegin Katran, İsmet Bulut, Fırat Saydın, Dilek Yavuz, Nazlı Deniz Cosar, Mustafa Katran","doi":"10.15586/aei.v53i2.1281","DOIUrl":"10.15586/aei.v53i2.1281","url":null,"abstract":"<p><strong>Background: </strong>In the perioperative period, patients are exposed to many agents that may cause hypersensitivity reaction; so, finding the culprit drug is important for patient safety in the event of the need for repeat anesthesia.</p><p><strong>Aim: </strong>Our aim was to share demographic data, clinical features, and diagnostic tests of patients who developed perioperative hypersensitivity (POH) and in whom the culprit drug was identified.</p><p><strong>Methods: </strong>Patients evaluated for POH between 2016 and 2024 were retrospectively analyzed. Results of anesthesia notes, agents used in anesthesia, skin prick test, and intradermal test (IDT) to determine the culprit drug were examined. Patients were interviewed by telephone and questioned about their reanesthesia status.</p><p><strong>Results: </strong>The files of 167,688 patients were analyzed; 405 patients were referred and tested for POH and 330 patients were excluded from the study because they had no history of POH or the culprit drug could not be identified. The study was completed with 75 patients. POH developed during the induction of anesthesia (I) in 18, maintenance (M) in 34, and at the end (E) in 23 patients. The median age was 48, out of which 89.3% (n = 67) were females. Reactions developed during genitourinary system surgery in 33.3% (n = 25), ear-nose-throat surgery in 17.3% (n = 13), and abdominal surgery in 17.3% (n = 13); anaphylaxis developed in 56% (n = 42) (I: 9; M: 21; E: 12); cutaneous involvement in 73.3% (n = 55); cardiovascular involvement in 41.3% (n = 31), respiratory system involvement in 56% (n = 42), and gastrointestinal involvement in 4% (n = 3); Brown grade 1 in 44% (n = 33) and grade 3 in 38.7% (n = 29); Ring and Messmer classification, grade 1 in 44% (n = 33); and cardiac arrest in five patients. For the distribution of culprit drugs: neuromuscular blocking agents (NMBAs) in 22.7%, opioids in 21.4%, hypnotics in 17.3%, and antibiotics in 14.6%. In four patients, multiple agents were determined. Skin prick test was positive in 35.1% and IDT positivity was found in 98.6%. Surgery was cancelled in 40% (n = 30), but it was determined that 50 patients (66.7%) underwent surgery after drug tests. All of them tolerated surgery.</p><p><strong>Conclusıon: </strong>A large number of patients were evaluated because we are a reference hospital. The most common culprit drug group in POH is NMBA; reanesthesia situations are safe after allergist evaluation.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"113-123"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria.","authors":"Fatma Arzu Akkuş, Fatih Çölkesen, Tuğba Önalan, Recep Evcen, Filiz Sadi Aykan, Mehmet Kılınç, Mehmet Emin Gerek, Şevket Arslan","doi":"10.15586/aei.v53i2.1207","DOIUrl":"10.15586/aei.v53i2.1207","url":null,"abstract":"<p><strong>Background: </strong>Omalizumab is a preferred treatment in antihistamine-refractory chronic spontaneous urticaria (CSU) patients. However, factors that may impact treatment response remain to be explored.</p><p><strong>Objective: </strong>This study aimed to examine the factors affecting treatment response in CSU patients receiving omalizumab.</p><p><strong>Methods: </strong>This was a retrospective study that included 123 patients who received omalizumab treatment for CSU between January 2015 and April 2024. After administering omalizumab, we evaluated therapeutic efficacy with the urticaria control test (UCT). According to UCT, patients were classified as complete responders, partial responders, and nonresponders.</p><p><strong>Results: </strong>The median age of the patients was 42 (31-50) years, and there were 77 (62.9%) female patients. Sixty-four (52%) patients exhibited complete response, and 43 (35%) patients exhibited partial response to omalizumab treatment, whereas 16 (13%) patients were nonresponders. Autoimmune disease (AID) was present in 31 (25.2%) patients. The most common AID was thyroid autoimmunity, seen in 24 (77.4%) patients. AID was significantly higher in omalizumab treatment nonresponders than in partial and complete responders. The presence of an autoimmune thyroid disease was an independent risk factor for failure to respond to omalizumab treatment. Baseline IgE levels were significantly higher in omalizumab treatment responders with a complete response compared to those with a partial response and nonresponders.</p><p><strong>Conclusion: </strong>Response to omalizumab treatment was influenced by the presence of an AID and baseline serum total IgE level. A concurrent autoimmune thyroid disease was found to be an independent risk factor affecting failed treatment response. Factors that can predict response to omalizumab treatment can help guide patients to more effective treatment.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"1-7"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Old Questions, new answers: real-world long-term efficiency of hymenoptera venom immunotherapy: prevalance of venom-induced anaphylaxis, risk factors, and field sting reactions.","authors":"Zeynep Yegin Katran, Ismet Bulut, Zeynep Ferhan Özşeker","doi":"10.15586/aei.v53i2.1237","DOIUrl":"10.15586/aei.v53i2.1237","url":null,"abstract":"<p><strong>Background: </strong>Hymenoptera venom allergy is a potentially life-threatening allergic reaction. Venom immunotherapy (VIT) is recommended to prevent severe allergic reactions. Field stings indicate the effectiveness of immunotherapy.</p><p><strong>Objective: </strong>The aim of this study was to investigate the prevalence of venom-induced anaphylaxis, risk factors, and field sting reactions during or after the completion of VIT.</p><p><strong>Methods: </strong>In this study, the records of patients who underwent VIT between 2015 and 2023 at one of the largest referral hospitals in Turkey were retrospectively analysed. The protocol followed during the initiation of immunotherapy, adverse reactions, clinical characteristics of the patients (including demographic characteristics, allergic diseases, laboratory findings), and field sting reactions during and after completion of immunotherapy were analysed.</p><p><strong>Results: </strong>A total of 194,526 unique patient files evaluated in the Allergy Outpatient Clinic between 2015 and 2023 were analysed. Of these, 384 patients were admitted with an allergic complaint following a bee sting. Among them, 113 patients (29.4%) were eligible for VIT. A total of 79 patients were included (F/M: 41/38). VIT was performed with honeybee venom in 39 patients, vespid venom in 36 patients, and both venoms in 4 patients. 62.0% (n=49) of the patients had been stung by a bee in the head and neck region. 69.6% (n=55) of the patients had a stage 3 reaction before VIT. The cluster scheme was applied to 54.4% (n=43) of all patients. There was no statistically significant difference in the number of field stings or the use of adrenaline autoinjectors between the VIT groups (p>0.05). Stage 3-4 reactions developed in 87.8% of patients stung in the head and neck region, compared to 53.3% of patients stung in other regions. During and after VIT, field stings were reviewed both from patient files and by follow-up inquiries during control visits. During VIT, field stings were observed in 19 patients. Systemic allergic reactions developed in 5 patients, and local allergic reactions developed in 6 patients; no allergic complaints were observed in 8 patients. After VIT was discontinued, 56 field sting reactions developed in 25 patients. Local allergic reactions developed in 9 patients, but no systemic allergic reactions were observed. Mastocytosis was diagnosed in a patient whose tryptase level was 42.4 and whose c-kit mutation was positive following haematological evaluation.</p><p><strong>Conclusions: </strong>This study confirms that the prevalence of venom-induced anaphylaxis was calculated to be 0.058%. Being stung in the head and neck region was identified as a risk factor for the development of stage 3-4 (severe allergic reactions).</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"82-88"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerance to cooked egg in infants with risk factors for egg allergy after early introduction of baked egg.","authors":"Claudia Rosillo Gil, Davinia Vázquez, Adrianna Machinena-Spera, Mª Del Mar Folqué Jiménez, Jaime Lozano-Blasco, Rosa Jiménez Feijoo, Olga Domínguez Sánchez, Monica Piquer Gibert, Marcia Dias Costa, Montserrat Alvaro-Lozano","doi":"10.15586/aei.v53i2.1257","DOIUrl":"10.15586/aei.v53i2.1257","url":null,"abstract":"<p><p>Egg allergy (EA),along with cow's milk allergy (CMA) and atopic dermatitis (AD is one of the most frequent allergies in children. Tolerance to food allergens seems to be related to the early and regular intake and the cooking method. The objective of this study is to prove that the introduction of baked eggs at 4-6 months of age and its daily maintenance for 6 months prevents EA. Controlled randomized clinical trial from February 2019 to November 2023 was done for all patients under 6 months of age, including those with CMA and/or AD without previous egg consumption. Skin prick test (SPT), specific immunoglobulin E (sIgE), basophil activation test (BAT), and oral food challenge (OFC) on baked eggs were performed at the beginning of the study (T0). Patients were classified into group A (nontolerant to baked egg) following an egg-free diet and group B (tolerant to baked egg). These were randomized into B1 who ate baked egg daily and B2 who avoided egg. Six months later, at time 1 (T1), an OFC to hard-boiled egg was performed. There were 27 patients in all. Those who ate baked egg daily for 6 months tolerated boiled eggs and only 47.4% of patients who followed an egg-free diet tolerated boiled eggs (<i>P</i>-value 0.012). All three tests-sIgE, SPT, and BAT-are considered good techniques to discriminate between tolerant versus not tolerant patients toward eggs.Patients under 6 months of age with CMA and/or AD who ate baked eggs daily for 6 months tolerated cooked eggs more frequently than patients who avoided eggs. Early introduction of baked eggs could prevent EA.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"59-66"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitization profile of Thai children with fish allergy.","authors":"Supaluk Tangvalelerd, Surapon Piboonpocanun, Unchalee Raungsirarak, Manaporn Sirichuwong, Pakit Vichyanond, Punchama Pacharn","doi":"10.15586/aei.v53i2.1209","DOIUrl":"10.15586/aei.v53i2.1209","url":null,"abstract":"<p><strong>Introduction: </strong>Fish allergies are common food allergies, and in Thailand, the prevalence of fish allergies in children ranges from 0.29% to 1.1%. Common fish allergens include parvalbumin, enolase, and aldolase.</p><p><strong>Method: </strong>This cross-sectional study included children with immunoglobulin E (IgE)-mediated fish allergies. The diagnosis was based on clinical history with a positive skin prick test (SPT) and/or specific IgE (sIgE). Serum IgE binding profiles to allergens in fish extracts were analyzed.</p><p><strong>Result: </strong>Eleven children, with a median age of 3 years, were recruited; the median age of onset was 1.25 years. Cutaneous symptoms were the most frequent clinical manifestation (63.6%). Tilapia and catfish were the most common triggers. All participants showed positive SPT and/or sIgE results for fish species. The immunoblot analysis revealed IgE binding to 40-50 kDa protein in all participants, while only seven participants (63.6%) showed IgE binding to the 11 kDa protein.</p><p><strong>Conclusion: </strong>Tilapia and catfish are the most common triggers of fish allergies in Thai children. The 40-50 kDa proteins were identified as a major fish allergen in tested cohort.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"108-112"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}